Study | Drug | Number (in diabetes subgroup) | CHD risk reduction (in overall study) | CHD risk reduction (in patients with diabetes) |
---|---|---|---|---|
Primary prevention | ||||
AFCAPS/TexCAPS13 | Lovastatin | 155 | 37% | 43% (NS) |
HPS14 | Simvastatin | 5963 | 27% | 27% (p<0.0001) |
Secondary prevention | ||||
CARE15 | Pravastatin | 586 | 23% | 25% (p = 0.05) |
4S16 | Simvastatin | 202 | 32% | 55% (p = 0.002) |
LIPID17 | Pravastatin | 782 | 24% | 19% (NS) |
4S (reanalysis)18 | Simvastatin | 483 | 32% | 42% (p = 0.001) |
LIPS19 | Fluvastatin | 202 | 22% | 47% (p = 0.04) |